Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation

This publication has 29 references indexed in Scilit:

• Treatment of Epstein–Barr Virus Infections: Chemotherapy, Antiviral Therapy, and Immunotherapy
  Published by Taylor & Francis ,2006
• Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation
  Blood, 2005
• Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes
  Journal of Clinical Oncology, 2005
• Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells
  American Journal of Transplantation, 2005
• Cellular Immunity to Epstein-Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post-Transplant Lymphoproliferative Disease
  American Journal of Transplantation, 2005
• Impaired recovery of Epstein-Barr virus (EBV)—specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease
  Blood, 2003
• Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration
  Blood, 2002
• B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome
  Bone Marrow Transplantation, 1999
• HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTION
  Annual Review of Immunology, 1997
• Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ Transplantation
  New England Journal of Medicine, 1991